Data-Driven Trial Optimization

The pharmaceutical industry and medical community is increasingly focused on Precision Medicine. Research has therefore shifted towards individual variability in genetics, lifestyle, biology – and body composition.

Designed to Play a Long-Term Role

Historically, the use of indirect measurements in patient selection has made it challenging to identify which patients are most likely to be positively impacted by a treatment. AMRA allows for the rapid selection of a homogenous patient group that shows the highest probability of benefiting from treatment, and provides a deeper understanding of treatment outcomes and efficacy. By delivering robust and validated findings compatible with existing MR vendors, AMRA can improve trial outcomes by providing an early understanding of disease progression and response to therapy.


AMRA® Profiler Research

Provides precise body composition measurements and advanced phenotyping using quantified MR imaging, a relatively new field in which AMRA is a world-leader.

Available Measurements
  • Visceral Adipose Tissue (VAT)
  • Abdominal Subcutaneous Adipose Tissue (ASAT)
  • Thigh Muscle Volume
  • Proton-Density Liver Fat Fraction
  • Total Adipose Tissue Volume (TAT)
  • Total Lean Tissue Volume (TLT)
  • Muscle Group Volumes
  • Intramuscular Adipose Tissue (IMAT)
  • Individual Muscle Volumes

Driving Therapeutic Innovation

Precise, automated body composition analysis can improve research and clinical decision making. AMRA is collaborating with industry leaders on data-driven trial optimization, advancing the understanding of metabolic status across a multitude of diseases.

Click on any of the diseases below to learn more

Get in touch!